1. Home
  2. GHRS vs ESQ Comparison

GHRS vs ESQ Comparison

Compare GHRS & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • ESQ
  • Stock Information
  • Founded
  • GHRS 2018
  • ESQ 2006
  • Country
  • GHRS Ireland
  • ESQ United States
  • Employees
  • GHRS N/A
  • ESQ N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • ESQ Commercial Banks
  • Sector
  • GHRS Health Care
  • ESQ Finance
  • Exchange
  • GHRS Nasdaq
  • ESQ Nasdaq
  • Market Cap
  • GHRS 774.1M
  • ESQ 838.1M
  • IPO Year
  • GHRS 2021
  • ESQ 2017
  • Fundamental
  • Price
  • GHRS $13.10
  • ESQ $100.89
  • Analyst Decision
  • GHRS Strong Buy
  • ESQ Hold
  • Analyst Count
  • GHRS 8
  • ESQ 3
  • Target Price
  • GHRS $30.63
  • ESQ $103.00
  • AVG Volume (30 Days)
  • GHRS 307.7K
  • ESQ 67.5K
  • Earning Date
  • GHRS 11-13-2025
  • ESQ 10-23-2025
  • Dividend Yield
  • GHRS N/A
  • ESQ 0.69%
  • EPS Growth
  • GHRS N/A
  • ESQ 12.45
  • EPS
  • GHRS N/A
  • ESQ 5.39
  • Revenue
  • GHRS N/A
  • ESQ $126,841,000.00
  • Revenue This Year
  • GHRS N/A
  • ESQ N/A
  • Revenue Next Year
  • GHRS N/A
  • ESQ $10.14
  • P/E Ratio
  • GHRS N/A
  • ESQ $18.73
  • Revenue Growth
  • GHRS N/A
  • ESQ 12.91
  • 52 Week Low
  • GHRS $6.00
  • ESQ $60.64
  • 52 Week High
  • GHRS $20.50
  • ESQ $107.25
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 45.98
  • ESQ 51.36
  • Support Level
  • GHRS $13.00
  • ESQ $98.89
  • Resistance Level
  • GHRS $14.96
  • ESQ $104.74
  • Average True Range (ATR)
  • GHRS 0.78
  • ESQ 2.50
  • MACD
  • GHRS -0.00
  • ESQ -0.33
  • Stochastic Oscillator
  • GHRS 28.46
  • ESQ 23.92

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.

Share on Social Networks: